Atherosclerosis Research

Atherosclerosis is a disease of the arterial system that is characterized by the accumulation of fatty deposits within arterial walls, known as 'atherosclerotic plaques'.

Atherosclerosis Research Products Targets

Products for Atherosclerosis Research - Page 11

Cat.No. Product Name Information/Activity
BCC7504 PD 146176 PD146176 (NSC168807) is a 15-Lipoxygenase (15-LO) inhibitor, which inhibits rabbit reticulocyte 15-LO with a Ki of 197 nM. PD146176 (NSC168807) has a dramatic effect in reducing atherogenesis.
BCC7288 STEARDA 105955-10-0
BCC6735 2-TEDC 132465-10-2
BCC2515 Zileuton Zileuton is a potent and selective inhibitor of 5-lipoxygenase with antiasthmatic properties.
BCC7412 Fexaramine Fexaramine is a small molecule farnesoid X receptor (FXR) agonist with 100-fold increased affinity relative to natural compounds.
BCC3790 GW3965 HCl GW3965 hydrochloride is a potent and selective liver X receptor (LXR) agonist with EC50s of 190 and 30 nM for hLXRα and hLXRβ , respectively.
BCC4500 GW4064 GW 4064 is a potent FXR agonist with an EC50 of 65 nM.
BCN2750 27-Hydroxycholesterol 27-Hydroxycholesterol is a selective estrogen receptor modulator and an agonist of the liver X receptor.
BCC1178 T0901317 T0901317 is a potent and selective agonist for LXR and FXR, with EC50s of 50 nM and 5 μM, respectively[1,2]. T0901317 induces its anti-proliferative and cytotoxic effects via an LXR-independent mechanism. T0901317 significantly suppresses cell proliferation and induces programmed cell death in a dose- and time-dependent manner. T0901317 can protect mice from high fat diet-induced obesity and insulin resistance.
BCC4273 LXR-623 LXR-623 is a brain-penetrant partial LXRα and full LXRβ agonist, with IC50s of 24 nM and 179 nM, respectively.